UPDATE 54: AUGUST 1 TO AUGUST 31, 2013
PDP FUNDERS GROUP
Items in blue or purple should be hyperlinked to the full text version; if I have made mistakes
many apologies. If you have any issues that you would like to include in the Update please
send them to Jane Rowley (jtfrowley@btinternet.com).
FUNDER ANNOUNCEMENTS (SINCE AUGUST 1, 2013)
Australia - AusAID
19 August 2013:
Investment in Medical Research
In June 2013, AusAID awarded grants to four organisations to advance new medical technologies
targeting diseases that disproportionately affect poor people in the Asia Pacific region:
 Global Alliance for TB Drug Development (TB Alliance)—to develop TB drugs.
 Aeras—to develop new TB vaccines.
 Medicines for Malaria Venture (MMV)—to develop drugs to treat malaria.
 Foundation for Innovative New Diagnostics (FIND)—to develop diagnostic tools for the control of
malaria and tuberculosis.
The total value of these grants is AUS$10 million.
UK - DFID
22 August 2013:
DFID invests to save millions from deadly diseases
.. Now, the Department for International Development is investing £138 million over the next 5 years
into 9 public-private partnerships to support the development of innovative new drugs, vaccines,
insecticides, diagnostic tools and microbicides to prevent, diagnose or treat these diseases. The
partnerships will bring together experts in the field while also sharing the costs and risks across
partners. …
The nine Product Development Partnerships (PDPs) DFID is supporting are:
 Drugs for Neglected Diseases initiative (DNDi): new drugs for sleeping sickness, skin sores, river
blindness and other lymphatic diseases spread by parasites and mosquitoes
 Medicines for Malaria Venture (MMV): new drugs for malaria, with a focus on treating malaria in
pregnancy and the relapsing form of malaria
 Innovative Vector Control Consortium (IVCC): new insecticides to control insects that carry malaria
and some of the neglected tropical diseases
 Foundation for Innovative New Diagnostics (FIND): new diagnostic tests for TB, malaria and
sleeping sickness
 TB Alliance: new drugs for people with TB and for those also infected with HIV
 Aeras: development of new vaccines to prevent TB infection
 New Products for Diarrhoea and Malaria (PATH): developing new drugs, diagnostics and vaccines
for diarrhoeal disease and diagnostics for malaria
 International AIDS Vaccine Initiative (IAVI): support for the development of new AIDS vaccines
 International Partnership for Microbicides (IPM): support for the development of womencontrolled HIV prevention technologies.
US - NIH
8 August 2013:
Investigational malaria vaccine found safe and protective
An investigational malaria vaccine has been found to be safe, to generate an immune system
response, and to offer protection against malaria infection in healthy adults, according to the results
of an early-stage clinical trial published Aug. 8 in the journal Science.
The vaccine, known as PfSPZ Vaccine, was developed by scientists at Sanaria Inc., of Rockville, Md.
The clinical evaluation was conducted by researchers at the National Institute of Allergy and
Infectious Diseases (NIAID), part of the National Institutes of Health, and their collaborators at the
UPDATE 54: AUGUST 1 TO AUGUST 31, 2013
Walter Reed Army Institute of Research, Silver Spring, Md., and the Naval Medical Research Center,
Bethesda, Md. …
The PfSPZ Vaccine is composed of live but weakened sporozoites of the species Plasmodium
falciparum, the most deadly of the malaria-causing parasites.
A number of follow-up studies are planned, including research to evaluate the vaccine’s different
dose schedules, possible protection against other Plasmodium strains and the durability of protection.
The researchers may also evaluate whether higher doses administered subcutaneously or
intradermally provide the same level of protection as that found in this study. …
Wellcome Trust
9 August 2013:
Toddler height linked to learning and adult risk of chronic disease in low and middle
income countries
Children from low- and middle-income countries who grow taller in height during the first two years
of life may do better at school and be healthier adults, whereas those who gain weight rapidly after
the age of two are at higher risk of chronic diseases in later life. …
29 August 2013:
Wellcome Trust and KU Leuven announce collaboration with Janssen for
development of dengue antiviral drugs
Researchers at the University of Leuven (KU Leuven) are joining forces with Janssen Pharmaceuticals
Inc. (Janssen) and the Wellcome Trust to discover and develop candidate antiviral drugs for the
prevention and treatment of dengue infection.
The collaboration will build on an existing three-year drug discovery programme at the Rega Institute
and the Centre for Drug Design and Discovery (CD3) at KU Leuven, supported by a Wellcome Trust
Seeding Drug Discovery Award. This effort resulted in the identification of a series of chemical
compounds that are highly potent inhibitors of dengue virus replication. The compounds have a novel
mechanism of action, are active against all four serotypes of the dengue virus including clinical
isolates, have a high barrier to resistance and have generated proof-of-concept data in animal
models. …
PDP PRESS RELEASES (SINCE AUGUST 1, 2013)
Aeras
2 August 2013:
Chinese Center for Disease Control and Prevention and Aeras Sign Agreement to
Collaborate on Tuberculosis Vaccine R&D
…The new collaboration between China CDC and Aeras will accelerate research efforts for new
vaccines by supporting studies that determine the incidence of TB infection, and will aim to
strengthen the capacity within China to conduct future vaccine clinical trials. …
China CDC is a nonprofit institution working in the fields of disease control and prevention, public
health management and provision of services. Aeras is a nonprofit biotech based in Maryland, USA
and Cape Town, South Africa, with the mission of advancing tuberculosis vaccines for the world. The
meeting also marks the official opening by Aeras of an office in Beijing to facilitate and strengthen
collaboration with Chinese researchers, partnerships that will be critical for developing tuberculosis
vaccines for China and the world. Aeras supports half of the vaccine candidates currently in clinical
trials, along with a portfolio of earlier stage candidates. …
19 August 2013:
AusAID Pledges AUS$2.5M “Shot in the Arm” for TB Vaccine R&D
The government of Australia has expanded its role in the global battle against tuberculosis, providing
a grant of AUS$2.5 million to fund the quest for an effective vaccine against a silent killer that infects
one out of three people worldwide.
The one-year grant to Aeras, the world’s largest non-profit biotech dedicated to advancing TB vaccine
research and development, will contribute to the effort of the Australian Agency for International
UPDATE 54: AUGUST 1 TO AUGUST 31, 2013
Development (AusAID) to combat diseases of poverty. …
29 August 2013:
UK Government Announces Grant to Aeras for New TB Vaccines
In a move to invest in potentially effective new solutions for an infectious disease that kills more than
1 million people every year and is becoming increasingly more difficult to control, the government of
the United Kingdom last week announced funding to support development of urgently needed
tuberculosis (TB) vaccines.
A new five-year grant from the Department for International Development will aid the mission of
Aeras, the world’s largest non-profit biotech dedicated to advancing TB vaccine research and
development. There currently is no effective vaccine to protect adults from the disease. This is the
DFID’s second grant to Aeras and a significant demonstration of support for the important role that
vaccines play in the global effort to eliminate TB. …
DNDi
22 August 2013:
UK Department for International Development (DFID) Commits £ 30 Million to DNDi
The UK Department for International Development (DFID) has announced its renewed support to the
Drugs for Neglected Diseases initiative (DNDi), allocating a total of £ 30 million (€ 35 million) over the
coming five years (2013-2018) to DNDi’s Research & Development (R&D) portfolio to fight neglected
diseases. This grant is part of DFID’s larger investment of £ 138 million in nine product development
partnerships (PPDs), including DNDi, for the development of new health tools to address povertyrelated diseases. …
EVI
14 August 2013:
EU awards Bellerophon Project €5.5 million
The Bellerophon Project, which is a consortium comprising Imaxio, the Jenner Institute at Oxford
University, the European Vaccine Initiative and Preclin Biosystems has been awarded a major FP7
grant to support development and phase I clinical trial of a S. aureus vaccine.
16 August 2013:
Sanaria's PfSPZ malaria vaccine yields unprecedented protection
Results of a phase I clinical trial of the Sanaria® - a grantee of EVI - PfSPZ Vaccine to combat malaria,
published 8 August 2013 in the online issue of Science magazine, show that the vaccine provided
complete protection against malaria in subjects who were exposed to Plasmodium falciparum
parasites. Plasmodium falciparum is the malaria parasite that causes more than 600,000 deaths
annually.
FIND
22 August 2013:
Government of Uganda launches an innovative project to accelerate elimination of
gambiense sleeping sickness using new diagnostic tools
An innovative project aimed at accelerating elimination ofTrypanosoma brucei gambiense sleeping
sickness in Uganda was launched on 30 July 2013 at a workshop held in Kampala, Uganda. The project
is being implemented by the Coordinating Office for Control of Trypanosomiasis in Uganda (COCTU),
in partnership with, among others, Makerere University, the Ugandan Ministry of Health, the
Ugandan Ministry of Agriculture, Animal Industry and Fisheries, and FIND. …
The new project is targeting the chronic form of sleeping sickness, which is caused by T.b. gambiense,
and is found in several districts located in north-western Uganda. It is based on three new diagnostic
tools recently developed by FIND and partners. The first test, named SD BIOLINE HAT and codeveloped by FIND and Standard Diagnostics Inc. of the Republic of Korea, is a rapid diagnostic test
(RDT) for screening individuals that detects host antibodies against parasites. This cheap and very
simple-to-use test can be performed by health workers with minimal training, using fresh blood from
a finger prick, and results are obtained after only 15 minutes. The test is unlike any screening tools in
use today, as it is stored at ambient temperature and does not require specialized equipment or
electricity, meaning that it can be used in very remote settings where most of the infected people
UPDATE 54: AUGUST 1 TO AUGUST 31, 2013
live. Patients who are found positive with the RDT are identified as suspects and have to undergo
additional tests to confirm disease. ….
29 August 2013:
FIND et le Canton de Genève luttent ensemble contre la maladie du sommeil
Dix ans après sa création, la Fondation pour de nouveaux diagnostics innovants (FIND), a reçu une
subvention de 60’000 CHF de la République et canton de Genève pour mettre en œuvre une nouvelle
stratégie qui devrait permettre d’accélérer la détection et l'élimination de la maladie du sommeil
dans le nord-ouest de l'Ouganda. …
IVCC
27 August 2013:
IVCC receives £12 million from the UK Department for International Development
(DfID) to develop the next generation of public health vector control tools
IVCC has been awarded £12 million over the next 4 years by the UK Department for International
Development (DfID) to support the development of new insecticides to combat
malaria. …
With this support from DfID and other major partners such as the Bill and Melinda Gates Foundation,
IVCC will move to the next phase in our development of the first new public health insecticides in 30
years. This novel chemistry will play a major part in bringing to an end this entirely preventable deadly
disease which kills hundreds of thousands of children annually, devastates families and keeps
countries poor.’ …
IAVI
21 August 2013:
U.K. Government pledges renewed funding to support IAVI’s quest for effective and
accessible AIDS vaccines
The International AIDS Vaccine Initiative (IAVI) is pleased to announce the renewed commitment from
the United Kingdom’s Department for International Development (DFID), which has confirmed a grant
to IAVI of £1 million ($1.57 million) annually for the next five years. …
Together with the contributions of other governments as well as foundations and other philanthropic
supporters, DFID investments over the last 15 years have already helped IAVI to build a
comprehensive portfolio of AIDS vaccine approaches and candidates. This includes a particular
emphasis on HIV types affecting developing countries, and on novel approaches such as broadly
neutralizing antibodies to overcome the enormous variability of HIV and its capacity to hide from the
body’s immune system. Furthermore, this funding has helped to establish lasting partnerships and
capacity for research in countries most affected by HIV and AIDS, including establishing laboratories
and clinics for medical research and providing training for scientists and healthcare workers across
Africa. Much of that research has been coordinated by IAVI’s U.K.-based laboratory at Chelsea and
Westminster Hospital, in collaboration with Imperial College London. Over the next 5 years, the
funding from the U.K. Government will allow IAVI to bring together expertise from academia and the
pharmaceutical sector, and from across regions, including the U.K. and Eastern and Southern Africa,
to collaboratively design and evaluate novel vaccine candidates, with the aim to deliver proof that at
least one can be fully developed into an effective vaccine to help prevent HIV infection or AIDS. …
IPM
22 August 2013:
IPM Receives £15 Million from UK Government to Advance Innovative Health
Products for Women
The International Partnership for Microbicides (IPM) announced today that it has received a £15
million (US$22.8 million) award over five years from the UK Department for International
Development (DFID) to advance new HIV prevention and multipurpose prevention technologies
(MPTs) for women. The announcement builds on recent scientific developments in the HIV
prevention field and global momentum around family planning. …
MMV
UPDATE 54: AUGUST 1 TO AUGUST 31, 2013
19 August 2013:
Australian first to advance malaria medicines
An Australian grant of $2.5 million to support the development of new antimalarial medicines has
been welcomed as a significant step towards addressing malaria as resistance increases in the Asia
Pacific region.
The grant to MMV is the first time AusAID has funded a global product development partnership to
address one of the world’s most neglected diseases. …
22 August 2013:
MMV receives funding to develop drugs to accelerate malaria eradication
The Bill and Melinda Gates Foundation has invested $160 million in MMV until 2018. This grant, to
support the discovery, development and delivery of new, affordable and effective antimalarials, will
contribute towards the Foundation’s vision of a malaria free world. …
22 August 2013:
DFID pledges further support for MMV
DFID has pledged £138 million until 2018 to nine product development partnerships, including £25
million for MMV, for the development of new tools to treat, control and ultimately eliminate some of
the world’s deadliest diseases. …
PATH
21 August 2013:
Bold PATH innovations win support at 2013 Saving Lives at Birth Grand Challenge




… This month, four promising solutions—two being developed by PATH and two with leading global
health partners—won funding through the Saving Lives at Birth innovation challenge. The awards will
provide the financial support necessary to move these potentially lifesaving ideas forward, helping to
expand the portfolio of low-cost, high-impact solutions for women and children worldwide. …
Two of PATH’s four winning submissions propose delivery technologies that are simple to use, lowcost, and may provide valuable alternatives to needle injection. These new options have the potential
to improve access to, and delivery of, key medicines to women during pregnancy, labor, and delivery.
Sublingual oxytocin tablets. Injections of oxytocin are currently used to prevent and treat postpartum
hemorrhage (uncontrolled bleeding), the leading cause of maternal death. The new tablet, designed
to dissolve quickly under the tongue, could provide an effective, easy to store, and easy to use
alternative in low-resource settings, where mothers have limited access to emergency obstetric care.
An alternative delivery method for magnesium sulfate. This new method allows health care workers
to deliver the drug rectally, which could provide a simpler and less painful way to quickly administer
this proven treatment to women suffering from preeclampsia or eclampsia, the second-leading cause
of death for mothers and babies.
Other successful submissions are collaborations with top health partners:
The Bilistick. Underlying health issues in newborns can cause a condition called hyperbilirubinemia,
which, if undetected and untreated, can lead to brain injury, hearing loss, or death. PATH is
partnering with a company called Bilimetrix to further develop the Bilistick, a rapid, low-cost test that
may improve detection and treatment and save lives in low-resource settings.
The uterine balloon tamponade. In Kenya and South Sudan, Massachusetts General Hospital, PATH,
and partners are working to increase the use of an improved next-generation uterine balloon
tamponade—a simple, effective device that can halt uncontrollable bleeding after birth in as few as
five minutes.
27 August 2013:
New PATH partnership will advance solutions for diarrhea and malaria
The United Kingdom’s Department for International Development (DFID) has selected PATH as a
partner in pioneering work to prevent, diagnose, and treat malaria and diarrhea in low-resource
settings. PATH will lead an innovative product development partnership to more quickly reach
children and adults with new lifesaving technologies for both diseases. …
Specifically our work will address:
 The gap between the availability of radical treatment for the malaria parasite Plasmodium
vivax and the diagnostic tools available to safely administer malaria treatment.
UPDATE 54: AUGUST 1 TO AUGUST 31, 2013


The market gap in affordable vaccines for rotavirus, the leading cause of severe diarrheal disease,
and the availability of a single-dose liquid rotavirus vaccine, as well as the lack of available
vaccine formulations for Shigella and enterotoxigenic Escherichia coli (ETEC), two other important
causes of severe diarrhea.
The limited supply and development pipeline for drugs to treat diarrhea in children, diagnostic
tools to differentiate among the pathogens that cause diarrhea, and new and alternative oral
rehydration products to treat diarrhea. …
30 August 2013:
Statement from PATH: Cervical cancer demonstration project in India
Today, the Indian Parliament’s Standing Committee on Health and Family Welfare released a report
critical of a cervical cancer vaccine demonstration project conducted in India from 2009 to 2010
through a collaboration among PATH, the Indian Council of Medical Research (ICMR), and the state
governments of Andhra Pradesh and Gujarat.
PATH welcomes public discussion about the role of vaccines in preventing life-threatening diseases
such as cervical cancer, and we thank the committee members for their time and effort in reviewing
this matter. We support the adoption of reasonable measures to further strengthen and clarify
protections for individuals participating in research projects. …
However, we are troubled by the report’s inaccurate characterization of this important work. …
The ICMR, India’s highest medical research authority, reviewed and approved the protocol for this
project, including its design and methodology. At the time of its review, the ICMR determined the
project was a post-licensure observational study and not a clinical trial. The project did not seek to
evaluate the efficacy or long-term safety of the vaccines, which had already undergone clinical
evaluation in India and had been licensed and approved by the Drugs Controller General of India.
The ICMR’s view was crucial, as it established the approval processes and protocols for the work that
followed. PATH designed the project protocols in compliance with the ICMR’s instructions and fully
complied with the ICMR’s requirements regarding the necessary approval processes and the
requirements of state governments regarding consent processes.
We believe that by following the guidance provided by the ICMR, as well as two state governments
and three ethical review committees, we designed a project that met or exceeded the country’s
existing regulatory standards for demonstration projects while providing the greatest health benefit
to Indian women. …
TB Alliance
16 August 2013:
AusAID Commits Support to TB Alliance to Advance New TB Drugs
The Global Alliance for TB Drug Development (TB Alliance) has received a grant from the Australian
Agency for International Development (AusAID) to support the advancement of the largest pipeline of
potential new TB drugs. This one-year $2.5 million grant funds further development of urgently
needed new TB treatments to combat the global epidemic, which is growing increasingly resistant to
today’s available therapies. TB Alliance received this support as part of Australia’s first set of grants to
fund new product development to treat diseases of poverty. …
22 August 2013:
DFID Supports Development of New TB Cures
TB Alliance has received a grant from the United Kingdom’s Department for International
Development (DFID) to support the advancement of new tuberculosis cures that have the potential to
save millions of lives. DFID’s investment in the TB Alliance builds on previous grants and comes at a
crucial time, as several treatments in the organization’s pipeline are in late-stage testing and are
poised to deliver near-term impact. These projects show promise to markedly improve TB therapy,
including drug-resistant TB, pediatric TB, and HIV/TB co-infection.
DFID’s grant to TB Alliance funds the development of urgently needed new TB regimens that can
tackle the global TB pandemic and the work to ensure these treatments obtain maximal uptake.
Support for TB Alliance’s efforts are part of DFID’s total investment of £138 million over the next five
years into nine public-private partnerships to support the development of innovative new drugs,
vaccines, insecticides, diagnostic tools, and microbicides to prevent, diagnose, or treat some of the
world’s most deadly and neglected diseases. …
UPDATE 54: AUGUST 1 TO AUGUST 31, 2013
TBVI
15 August 2013:
Tuberculosis costs EU €5.9 billion per year
The economic burden of tuberculosis (TB) in the European Union amounts to a total of
€5,898,298,315 per year, according to a conservative calculation. This is the conclusion of a scientific
study, published today in the European Respiratory Journal, led by the University Hospital SchleswigHolstein in Kiel, Germany. …
RECENTLY RELEASED PDP REPORTS/ BRIEFING PAPERS/ ARTICLES
Articles in Peer Reviewed Journals
•
•
•
•
•
An Improved Kilo-scale Synthesis of 2-Bromo-4-nitro-1H-imidazole: A Key Building Block of
Nitroimidazole Drugs. Rao S et al. Org. Process Res. Dev., August 2013.
Benznidazole and Posaconazole in Experimental Chagas Disease: Positive Interaction in
Concomitant and Sequential Treatments. de Figueiredo Diniz L et al. PLoS NTD, August 2013.
A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery .Jiménez-Díaz MB
et al. PLoS ONE 8(6): e66967. doi:10.1371/journal.pone.0066967
Open source drug discovery - A limited tutorial. Robertson MN et al. Parasitology / FirstView
Article pp 1-10. Published online: 28 August 2013
Modeling the public health impact of malaria vaccines for developers and policymakers. Nunes
JK et al. BMC Infectious Diseases 2013, 13:295
Other PDP Publications/ Briefing papers

DNDi Annual Report 2012. August 2013.
RECENTLY RELEASED PDP RELATED REPORTS/ BRIEFING PAPERS/ ARTICLES
Reports/ briefing papers/ books



HIV Preventives: Technology and Market Landscape. First Edition. UNITAID. August 2013.
International Regulatory Harmonization Amid Globalization of Drug Development Workshop
Summary. IOM Worskhop Summary. August 1, 2013
Seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine in
children: A field guide. WHO Global Malaria Programme. August 2013.
PDP RELATED NEWS/ ARTICLES (SINCE AUGUST 1, 2013)
HIV/AIDS






Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk
heterosexuals: Subgroup analyses from a randomized trial. Murnane P et al. AIDS.
9 August 2013; 27(13):2155-2160.
Hormonal contraception decreases bacterial vaginosis but oral contraception may
increase candidiasis: Implications for HIV transmission. van de Wijgert J et al. AIDS.
9 August 2013; 27(13):2141-2153.
Where to deploy pre-exposure prophylaxis (PrEP) in sub-Saharan Africa? Verguet S
et al. Sex Transm Infect. 2 August 2013
Recruiting and educating participants for enrollment in HIV-vaccine research:
Ethical implications of the results of an empirical investigation. Sifunda S et al.
Public Health Ethics. 2 August 2013
High acceptability of HIV pre-exposure prophylaxis but challenges in adherence
and use: Qualitative insights from a phase I trial of intermittent and daily PrEP in
at-risk populations in Kenya. Van der Elst E et al. AIDS Behav.. 2 August 2013
Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the
beginning. Kwong P et al. Nature Reviews Immunology. 23 August 2013; 13:693701.
UPDATE 54: AUGUST 1 TO AUGUST 31, 2013








Malaria


TB




Vaccines
Nutrition







Other






The evolving design and methods for trials evaluating the safety of candidate
vaginal microbicides: A systematic review. Jespers V et al. Sexually Transmitted
Diseases. 23 August 2013; 40(9):729-736.
6 August 2013: Wanted: a standard model of HIV and Aids diagnostics for Africa
6 August 2013: Trials challenging HIV drug doses could usher in huge cost cuts
6 August 2013: HIV drug awarded tentative approval by FDA
7 August 2013: China revokes patent on Gilead's Viread
17 August 2013: Kenya, Rwanda and UK in joint HIV/AIDS vaccine trial
19 August 2013: Pill can prevent fatal TB in HIV patients
26 August 2013: UNITAID Launches first-ever comprehensive report on HIV
prevention products
28 August 2013: Cochrane review finds larvae control cuts malaria cases
Further shrinking the malaria map: how can geospatial science help to achieve
malaria elimination? Clements ACA et al. The Lancet Infectious Diseases, Volume
13, Issue 8, Pages 709 - 718, August 2013
Domestic and donor financing for tuberculosis care and control in low-income and
middle-income countries: an analysis of trends, 2002—11, and requirements to
meet 2015 targets. Floyd K et al. The Lancet Global Health, Volume 1, Issue 2,
Pages e105 - e115, August 2013
Rapid diagnosis of pulmonary tuberculosis in African children in a primary care
setting by use of Xpert MTB/RIF on respiratory specimens: a prospective study. Zar
HJ et al. The Lancet Global Health, Volume 1, Issue 2, Pages e97 - e104, August
2013
Universal access to care for multidrug-resistant tuberculosis: an analysis of
surveillance data. Falzon D et al. The Lancet Infectious Diseases, Volume 13, Issue
8, Pages 690 - 697, August 2013
Effect of improved tuberculosis screening and isoniazid preventive therapy on
incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro,
Brazil. Durovni B et al. Lancet Infectious Diseases. Early Online Publication, 16
August 2013
7 August 2013: New compound shows promising signs of treating TB
14 August 2013: Encouraging discovery made for dengue vaccine development
14 August 2013: 10 of the Most Important Diseases With No Licensed Vaccine
28 August 2013: Biotechnology company launches new typhoid vaccine
Evidence-based interventions for improvement of maternal and child nutrition:
what can be done and at what cost? Bhutta ZA et al. The Lancet, Volume 382,
Issue 9890, Pages 452 - 477, 3 August 2013
The politics of reducing malnutrition: building commitment and accelerating
progress. Gillespie S et al. The Lancet, Volume 382, Issue 9891, Pages 552 - 569, 10
August 2013
Nutrition-sensitive interventions and programmes: how can they help to
accelerate progress in improving maternal and child nutrition? Ruel MT et al. The
Lancet, Volume 382, Issue 9891, Pages 536 - 551, 10 August 2013
1 August 2013: Op-ed examines the importance of public-private partnerships for
global health
1 August 2013: Partnerships, capacity building needed to strengthen universities in
developing nations
15 August 2013: Health research is essential for progress towards universal health
coverage
21 August 2013: Cipla chief calls for 'obligatory' drugs licences
21 August 2013: USAID’s Frontlines highlights R&D projects in top successes list
27 August 2013: FDA details ethics panel duties in clinical trials
UPDATE 54: AUGUST 1 TO AUGUST 31, 2013
UPCOMING MEETINGS

October 6-11 2013: 6th MIM Pan-African Malaria Conference Durban, South Africa

October 7-10 2013: AIDS Vaccine 2013. Barcelona. Spain

October 20-24 2013: Seventh EDCTP Forum. Dakar, Senegal.

October 30 - November 3 2013: Union World Conference on Lung Health. Paris. France

October 31 2013: FIND & TB Alliance Symposium. Paris. France.

December 4 2013: EVI Rendez-Vous 2013. Heidelberg, Germany.

December 5 2013: Best Science for the Most Neglected. Where Do We Stand 10 Years On? DNDi
& Institut Pasteur. Paris. France